Proactive Investors - Run By Investors For Investors

Living Cell Technologies maps timeline to clinical results from Parkinson's trial

The halt will remain in place until Monday 13th November 2017.
Living Cell Technologies maps timeline to clinical results from Parkinson's trial
The company's shares are in pre-open

Living Cell Technologies Ltd (ASX:LCT) is preparing some highly anticipated results from the NTCELL Parkinson's disease clinical trial, which are expected on Friday 10th November 2017.

Shares in the company had been rising on the anticipation, recently hitting $0.28, but have lost some momentum and were changing hands at $0.205 at yesterday's close.

Mid-year shares could have been snapped up around the $0.11 range.

The ASX has this morning granted Living Cell a trading halt to prepare details from the trial.

The halt will remain in place until the opening of trade on Monday 13th November 2017, or earlier if an announcement is made to the market.

View full LCT profile View Profile

Living Cell Technologies Ltd Timeline

Related Articles

1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use